MAP2K7 and melanoma: YAP1 is negatively correlated with tumor response to BRAFi or RAF/MEK dual inhibition in melanoma patients 178, is recurrently amplified in KRAS-independent relapsed PDAC tumors 179, and is nuclear-localized and activated after KRAS suppression in relapsed lung tumors 180.